UroGen Pharma Ltd. Operating Lease, Right-of-Use Asset, Amortization Expense
UroGen Pharma Ltd. (URGN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $590.00K, a 14.34% increase year-over-year.
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $577.00K, a 35.76% increase year-over-year.
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $604.00K, a 153.78% increase year-over-year.
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $559.00K, a 182.32% increase year-over-year.
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.10M, a 145.51% increase from fiscal 2024.
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $857.00K, a 5.09% decline from fiscal 2023.
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $903.00K, a 1.12% increase from fiscal 2022.
- UroGen Pharma Ltd. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $893.00K, a 5.20% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $590.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.17M 10-Q · filed 2026-08-05 | $1.77M derived: sum of 3 quarters · filed 2026-08-05 | $2.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $577.00K 10-Q · filed 2026-05-06 | $1.18M derived: sum of 2 quarters · filed 2026-05-06 | $1.74M derived: sum of 3 quarters · filed 2026-05-06 | $2.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.16M derived: sum of 2 quarters · filed 2026-03-02 | $1.68M derived: sum of 3 quarters · filed 2026-08-05 | $2.10M 10-K · filed 2026-03-02 |
| 2025-09-30 | $559.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.07M derived: sum of 2 quarters · filed 2026-08-05 | $1.50M 10-Q · filed 2025-11-06 | $1.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $516.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $941.00K 10-Q · filed 2026-08-05 | $1.18M derived: sum of 3 quarters · filed 2026-08-05 | $1.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $425.00K 10-Q · filed 2026-05-06 | $663.00K derived: sum of 2 quarters · filed 2026-05-06 | $861.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $436.00K derived: sum of 2 quarters · filed 2026-03-02 | $629.00K derived: sum of 3 quarters · filed 2026-03-02 | $857.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $391.00K derived: sum of 2 quarters · filed 2025-11-06 | $619.00K 10-Q · filed 2025-11-06 | $853.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $421.00K 10-Q · filed 2025-08-07 | $655.00K derived: sum of 3 quarters · filed 2025-08-07 | $884.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $228.00K 10-Q · filed 2025-05-12 | $462.00K derived: sum of 2 quarters · filed 2025-05-12 | $691.00K derived: sum of 3 quarters · filed 2025-05-12 | $913.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $463.00K derived: sum of 2 quarters · filed 2024-11-06 | $685.00K derived: sum of 3 quarters · filed 2024-11-06 | $903.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $229.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $451.00K derived: sum of 2 quarters · filed 2024-11-06 | $669.00K 10-Q · filed 2024-11-06 | $883.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $440.00K 10-Q · filed 2024-08-13 | $654.00K derived: sum of 3 quarters · filed 2024-08-13 | $850.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $218.00K 10-Q · filed 2024-05-13 | $432.00K derived: sum of 2 quarters · filed 2024-05-13 | $628.00K derived: sum of 3 quarters · filed 2024-05-13 | $870.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $410.00K derived: sum of 2 quarters · filed 2024-03-14 | $652.00K derived: sum of 3 quarters · filed 2024-03-14 | $893.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $438.00K derived: sum of 2 quarters · filed 2023-11-14 | $679.00K 10-Q · filed 2023-11-14 | $917.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $242.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $483.00K 10-Q · filed 2023-08-10 | $721.00K derived: sum of 3 quarters · filed 2023-08-10 | $956.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $241.00K 10-Q · filed 2023-05-11 | $479.00K derived: sum of 2 quarters · filed 2023-05-11 | $714.00K derived: sum of 3 quarters · filed 2023-05-11 | $946.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $473.00K derived: sum of 2 quarters · filed 2023-03-24 | $705.00K derived: sum of 3 quarters · filed 2023-03-24 | $942.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $467.00K derived: sum of 2 quarters · filed 2022-11-10 | $704.00K 10-Q · filed 2022-11-10 | $1.20M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $469.00K 10-Q · filed 2022-08-11 | $963.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $237.00K 10-Q · filed 2022-05-10 | $731.00K derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $494.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.63M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $1.13M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |